PIGA Congenital Disorder of Glycosylation (MCAHS2)

CDG Care Awards $20,000 Research Grant for Next Phase in PIGA-CDG Research

Featured in CDG Care’s November 2018 Newsletter (Volume 6):
CDG CARE and researchers from Osaka University in Japan are furthering their partnership to find effective supplements for use in persons diagnosed with a PIGA-CDG mutation.
Earlier this year, CDG CARE awarded a $20,000 research grant to the Osaka University research team in a project designed to determine if specific supplements are effective and to what extend they improve the degree of GPI-anchor deficiency. With positive results and significant progress made through these studies, CDG CARE is excited to announce that a second research grant in the amount of $20,000 has been awarded to the Osaka University research team. The focus of this second award will enable the researchers to move into in-vivo testing designed to measure the effectiveness of the supplements in mice.
Building on promising results of the in-vitro studies already completed, this next phase is critical in determining the bioavailability of these supplements and the extent to which GPI-anchor deficiency is improved, and the impact of different dosages on effectiveness. This data helps to further PIGA-CDG research and is a critical step in discovering a potential treatment for those impacted by this mutation.